Skye Bioscience (SKYE) Convertible Debt (2018 - 2021)
Skye Bioscience (SKYE) posted quarterly Convertible Debt of $1.4 million for Q3 2021, up 73.5% year-over-year from $789694.0 in Q3 2020, and up 12.41% quarter-over-quarter from $1.2 million in Q2 2021.
Skye Bioscience (SKYE) Convertible Debt (2018 - 2021) Analysis & Trends
Skye Bioscience (SKYE) has reported Convertible Debt for 4 consecutive years, with $1.4 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Convertible Debt rose 73.5% year-over-year to $1.4 million; the TTM figure through Sep 2021 stood at $1.4 million (up 73.5% YoY), while the FY2020 annual figure was $931103.0, up 140.55% from the prior year.
- Convertible Debt climbed to $1.4 million in Q3 2021 per SKYE's latest filing, from $1.2 million in the prior quarter.
- Across five years, Convertible Debt topped out at $3.3 million in Q3 2019 and bottomed at $387070.0 in Q4 2019.
- Historically, Convertible Debt has averaged $1.5 million across 4 years, with a median of $1.1 million in 2021.
- On a YoY basis, Convertible Debt climbed as much as 140.55% in 2020 and fell as far as 82.23% in 2020.
- Skye Bioscience's Convertible Debt stood at $1.4 million in 2018, then plunged by 71.56% to $387070.0 in 2019, then surged by 140.55% to $931103.0 in 2020, then jumped by 47.15% to $1.4 million in 2021.
- Business Quant data shows SKYE's Convertible Debt at $1.4 million in Q3 2021, $1.2 million in Q2 2021, and $1.1 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - |
| 10 | Skye Bioscience | 10.78 Mn | 10.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 1.22 Mn |
| Mar 31, 2021 | 1.07 Mn |
| Dec 31, 2020 | 931,103.00 |
| Sep 30, 2020 | 789,694.00 |
| Jun 30, 2020 | 651,461.00 |
| Mar 31, 2020 | 517,780.00 |
| Dec 31, 2019 | 387,070.00 |
| Sep 30, 2019 | 3.30 Mn |
| Jun 30, 2019 | 3.10 Mn |
| Mar 31, 2019 | 2.91 Mn |
| Dec 31, 2018 | 1.36 Mn |